GENERAL ANNOUNCEMENT::HOLDING ANNOUNCEMENT - UPDATE

Issuer & Securities

Issuer/ Manager

SINGAPORE PAINCARE HOLDINGS LIMITED

Securities

SINGAPORE PAINCARE HOLDINGS LIMITED - SGXE51400773 - FRQ

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date &Time of Broadcast

02-Apr-2025 17:32:13

Status

New

Announcement Sub Title

HOLDING ANNOUNCEMENT - UPDATE

Announcement Reference

SG250402OTHRZTG7

Submitted By (Co./ Ind. Name)

Dr. Lee Mun Kam Bernard

Designation

Executive Chairman and Chief Executive Officer

Description (Please provide a detailed description of the event in the box below)

Please refer to the attachment.

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor") in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

Attachments

SPCH-Holding announcement-Update.pdf

Total size =605K MB

SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.: 201843233N (Incorporated in the Republic of Singapore)

HOLDING ANNOUNCEMENT - UPDATE

The Board of Directors (the "Board") of Singapore Paincare Holdings Limited (the "Company") refers to the announcement released by the Company on 3 March 2025 informing shareholders of the Company that the Company had been approached in relation to a possible transaction involving the shares in the Company (the "Possible Transaction").

The Board wishes to update shareholders of the Company that as at the date of this announcement, confidential discussions in relation to the Possible Transaction are still ongoing.

Shareholders and any other investors should note that there is no certainty or assurance that any specific or definitive transaction will eventually materialise or be carried out as a result of such discussions. If and when there is any material development, the Company will, in compliance with the applicable rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist, make an announcement at the appropriate time.

In the meantime, shareholders of the Company are advised to exercise caution when dealing in the shares of the Company, pending any definitive announcement(s) from the Company. In the event of any doubt, shareholders of the Company should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

The Directors of the Company (including those who may have delegated detailed supervision of the preparation of this announcement) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this announcement are fair and accurate and that no material facts have been omitted from this announcement, the omission of which would make any statement in this announcement misleading, and they jointly and severally accept responsibility accordingly. Where any information in this announcement has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the Directors has been to ensure, through reasonable enquiries, that such information has been accurately and correctly extracted from such sources or, as the case may be, accurately and correctly reflected or reproduced in this announcement in its proper form and context.

BY ORDER OF THE BOARD

Singapore Paincare Holdings Limited

Dr. Lee Mun Kam Bernard Executive Chairman and Chief Executive Officer 2 April 2025

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**") in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.